Capital Advisors Wealth Management LLC Makes New $58,000 Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Capital Advisors Wealth Management LLC bought a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 21,800 shares of the biopharmaceutical company’s stock, valued at approximately $58,000.

Other large investors have also added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $9,568,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Esperion Therapeutics by 120.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 225,767 shares during the last quarter. Jump Financial LLC purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $77,000. GSA Capital Partners LLP boosted its stake in shares of Esperion Therapeutics by 159.1% during the 3rd quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company’s stock worth $1,094,000 after acquiring an additional 685,733 shares during the last quarter. Finally, Spire Wealth Management boosted its stake in shares of Esperion Therapeutics by 69.2% during the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 7,267 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Down 4.1 %

Shares of ESPR stock opened at $2.09 on Wednesday. The stock has a market cap of $395.97 million, a P/E ratio of -2.11 and a beta of 1.00. Esperion Therapeutics, Inc. has a 52 week low of $0.70 and a 52 week high of $3.40. The company’s fifty day simple moving average is $2.29 and its two-hundred day simple moving average is $2.39.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.42. The company had revenue of $137.74 million during the quarter, compared to analysts’ expectations of $53.11 million. On average, analysts anticipate that Esperion Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ESPR. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Tuesday, May 21st. StockNews.com cut shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 17th. Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, May 7th. Finally, Bank of America cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $2.90 to $2.50 in a research note on Thursday, June 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.83.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.